MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • MassDevice Today
    • Cardiovascular
    • Clinical Trials
    • Legal News
    • Orthopedics
    • Regulatory/Compliance
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • More MedTech
    • Cosmetic/Aesthetic
    • Diabetes
    • Dialysis
    • Distribution
    • Imaging
    • Otolaryngology Ear, Nose & Throat
    • Pharma
    • Respiratory
    • Wound Care
  • Blog
  • DeviceTalks Podcasts
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Job Board
    • Leadership in Medtech
    • Manufacturer Search
    • Videos
    • White Papers
  • DeviceTalks
Home » Inside Hologic’s evolving definition of women’s healthcare

Inside Hologic’s evolving definition of women’s healthcare

August 13, 2018 By Sarah Faulkner Leave a Comment

Share

HologicHologic (NSDQ:HOLX), known in the medtech industry for its mammography and diagnostics devices, is rethinking what it means to be a women’s healthcare company.

The 6,000-person company wants to expand its reach to include products that care for women’s well-being, as well as their health – a concept that Dr. Edward Evantash honed when he led the Ob/Gyn division at Tufts Medical Center.

“The beauty of being an Ob/Gyn is that you really take care of women throughout the continuum of their lifecycle,” Evantash, Hologic’s medical director & VP of global medical affairs, told MassDevice.com. “You get the full breadth of medical care for women. That’s essentially Hologic.”

When Evantash first landed at Hologic in 2009, the company was focused on a select group of products: its ThinPrep cervical cancer test, fetal fibronectin test and breast & skeletal health division.

But early in his tenure, Evantash noted that there was a shift afoot in the company’s strategy. Hologic was actively acquiring and developing products that helped to expand its reach across the spectrum of a woman’s life.

‘We kind of fly under the radar’

The Massachusetts-based company was founded in 1985 and has since grown into one of the largest medical device companies in the U.S. – it brought in roughly $3 billion in revenue last year. But even as it looks to expand into new businesses, it’s not backing away from the ones that it knows best: diagnostic tests and devices.

Hologic has an array of tests on the market, including the leading products used to screen for sexually transmitted diseases – marketed under the Aptima brand. It even created a fully-automated system to help laboratories process different assays simultaneously, called the Panther system.

The company positions its diagnostic tests as hugely beneficial to a healthcare system overwhelmed by cost. Take for example a test that determines the risk of preterm labor in women who show up to the hospital with contractions, Evantash said.

“Years ago we would just admit all those patients to the hospital for weeks. Think about the cost not just to the hospital but also her being out of work and the impact on her family,” he explained. “We have a test with a negative predictive value that’s almost over 99%.”

Preventive care is not always top-of-mind for the public, but former CFO Bob McMahon, who moved to Agilent Technologies this month, said the company is working to help change that by educating patients about the value of diagnostic screening.

McMahon

“Too many women don’t have their mammograms as the guidelines say and the same goes with the screening around sexually transmitted diseases. There are clinical guidelines out there and still there’s a tremendous amount of opportunity to create awareness about co-testing for cervical cancer and so forth,” McMahon said. “I personally believe that our products stand out because they’re not just ‘me too’ products. They actually have a clinical benefit that we can communicate to a woman. If everyone understood that 3D mammography detects 20% to 65% more invasive cancers than traditional 2D mammography while also reducing callbacks up to 40%, who wouldn’t want to have that?”

Hologic is a global company – its largest market after the U.S. is China – but the company hopes to expand into new markets where its diagnostic tech could be especially applicable, including India and Latin America.

“We kind of fly under the radar, but we’re global,” McMahon told us. “One of the things that all governments are struggling with now is the growing healthcare burden, so we’re working with governments and with some of our distributors to understand what we bring to the table and helping drive that path for reimbursement and access.”

“[Cervical cancer] used to be our number one cancer for women’s reproductive systems, until the Pap test was introduced. And now we don’t think of it as a major cancer any longer. It is one of the most common cancers for women outside the United States, especially in third-world countries. What could we do with our technologies to make them more accessible to some of those communities in those countries?” Evantash added.

(Learn more about the company’s vision from Hologic CEO Steve MacMillan at DeviceTalks Boston, Oct. 8-10)

Bringing AI and patient preference to women’s health

Hologic is among the many medtech companies that see the future of medical technology in smarter, more connected systems. The excitement about the potential of artificial intelligence is palpable among the medtech industry and the team at Hologic is no exception.

“Technology is advancing, especially the world of artificial intelligence. We’re looking at whether or not we can integrate some of our mammography screenings with the algorithms that are used for detection of both breast density and breast cancers,” Evantash said. “For our ThinPrep test, we’re seeing how we can make reading a Pap test more standardized instead of having cytotechnologists looking at it.

“Applying that across other technologies that we have, I think, is certainly a potential future for us,” he added.

Hologic is aligned with other industry trends, the executives noted. Through its purchase of Interlace Medical in 2011, Hologic acquired a tissue removal device designed for uterine fibroids and polyps. Since then, the company has expanded its MyoSure portfolio to include devices that can be used in a doctor’s office without anesthesia.

“We’re really trying to incorporate where we think medicine has gone, where physicians are practicing – moving out of the operating room and into the office,” McMahon said.

Changing the definition of ‘women’s healthcare’

Last year, Hologic made a billion-dollar-bid for medical aesthetics company Cynosure, marking its move into the periphery of women’s healthcare.

Cynosure brought with it nearly $434 million in annual sales, as well as a portfolio of devices like the first FDA-approved laser treatment for non-invasive body contouring, SculpSure.

The $1.65 billion acquisition also included Cynosure’s MonaLisa Touch device, a laser designed to restore vaginal health by generating collagen and elastin. That device, according to Evantash, could help address vaginal and hormonal changes that occur as a result of menopause or a hysterectomy.

Ed Evantash Hologic

Evantash

“There’s a lot of anecdotal experience about how it works or doesn’t work. We are committed to actually looking at the data on how these devices and how specifically MonaLisa Touch works to treat something that is incredibly disturbing to women and disruptive to their lifestyle,” he said.

McMahon added that the company decided to pursue medical aesthetics because the team viewed it as an emerging area that was complementary to the rest of Hologic’s businesses.

“The benefit of us coming into that space is that we have a reputation of operating based on the clinical benefits of all of our products,” he said. “And we’re committed to proving that [these medical aesthetic devices] do really work.”

Based on the FDA’s recent warning letters to seven device manufacturers (including Hologic’s Cynosure), the industry has its work cut out for them when it comes to proving the safety and efficacy of devices designed for “vaginal rejuvenation” procedures.

“We’ve recently become aware of a growing number of manufacturers marketing ‘vaginal rejuvenation’ devices to women and claiming these procedures will treat conditions and symptoms related to menopause, urinary incontinence or sexual function. The procedures use lasers and other energy-based devices to destroy or reshape vaginal tissue. These products have serious risks and don’t have adequate evidence to support their use for these purposes. We are deeply concerned women are being harmed,” FDA chief Dr. Scott Gottlieb said in prepared remarks.

“Hologic, Inc. and our medical aesthetics division, Cynosure, are aware that the FDA has issued a letter expressing concerns regarding ‘vaginal rejuvenation’ procedures. As a leader in women’s health, Hologic has a strong track record of rooting our products in science and clinical evidence so, we take the contents of this letter seriously. We are evaluating the letter in full and will collaborate with the agency to ensure all product communications adhere to regulatory requirements,” Jane Mazur, VP of divisional communications at Hologic, told us.

Reflecting on his four years at Hologic, McMahon said that he doesn’t think Hologic’s mission has changed, but it has evolved.

“We were a leader in women’s health. We are still that today. But I think the notion of how we view women’s health has expanded,” he said. “Now, it’s more encompassing to include both health and well-being.”

“I had a philosophy in clinical practice and in academics to be innovative, cutting edge and completely committed to my patients and their families. And that’s why I came to Hologic – because they had the same philosophy and we still do,” Evantash said.

Filed Under: Business/Financial News, Food & Drug Administration (FDA), Women's Health Tagged With: Cynosure Inc., Hologic

In case you missed it

  • Affluent Medical touts results of endovascular aneurysm repair study
  • NeoTract’s UroLift system gains expanded insurance coverage
  • Innovasive rebrands as Amplify Surgical
  • Report: FDA panel wants more extensive data, quality of life outcomes for vaginal mesh products
  • These medtech companies raised the most VC in 2018
  • IEEE publishes safety standards draft for medtech interoperability
  • Senseonics partners to provide veterans with Eversense CGM
  • FDA goes after California stem cell doc for unapproved breast implant device
  • FTC wants more details on $4B Boston Scientific-BTG tie-up
  • Tandem wins interoperable claim for insulin pump from FDA
  • Nevro files patent infringement suit against Stimwave
  • A record year for device innovation
  • Soterix Medical launches tDCS trial for cocaine addiction
  • Corindus asks FDA for expanded neurosurgery indication for CorPath GRX
  • FDA green-lights early feasibility trial for Foldax’s Tria biopolymer heart valve
  • Wisc. Dem seeks co-sponsors for bill to repeal medical device tax
  • Titan Medical hopeful for Q4 FDA IDE trial launch for Sport robotic platform

RSS From Medical Design & Outsourcing

  • FDA clears Safe Medical Design’s urethral catheter
    Safe Medical Design (San Francisco) said that FDA has cleared its Signal Catheter for commercialization in the United States. The 100% silicone foley catheter features a novel hub design allowing the catheter to reduce excessive balloon pressure in the event the catheter is improperly placed. Each year in the United States there are as many as 500,000… […]
  • These medtech companies raised the most VC in 2018
    Venture capital firms invested more than $2.9 billion in medical device companies in 2018 — a slight increase from the $2.8 billion raised in 2017, according to a MoneyTree report from PricewaterhouseCoopers (PwC) and CB Insights. Both the first and second quarters of 2018 saw an increase in investments, totaling nearly $778 million and $786 million… […]
  • ODU touts Medi-Snap Advanced plastic circular connector for medical applications
    ODU (Camarillo, Calif.) recently announced that it is introducing its Medi-Snap Advanced plastic circular connector to the North American market. ODU describes the Medi-Snap as lightweight and cost-efficient. It’s a plastic circular connector with high chemical resistance ideal for medical, industrial and test and measurement applications, according to the company. The autoclavable connector is IEC 60601-1 compliant and… […]
  • Regulatory software company Complion raises $7M
    Complion (Cleveland) — a maker of regulatory software for clinical research sites — recently announced that it has raised $7 million in its latest funding round. Beringea led the Series B round, the company announced on Feb. 12. The round ended up being oversubscribed, thanks to interest from existing investors including the Ohio Innovation Fund, JumpStart… […]
  • These new titanium strip grades could enable better neuromodulation devices
    Officials at Ametek Specialty Metal Products (Collegeville, Pa.) think their new titanium strip grades for medical applications could enable more innovation in the fast-growing neuromodulation device sector. Ametek’s Hamilton Precision Metals and SMP Wallingford businesses have proprietary production processes for the new titanium grades — grades 9 and 23. They manufacture thin strips of the titanium through cold… […]
  • CoorsTek Bioceramics touts composite ceramic material
    CoorsTek Bioceramics officials think testing and clinical feedback since 2011 has shown their CeraSurf-p alumina matrix composite ceramic material to be a state-of-the-art ceramic bearing material for total hip arthroplasty. CoorsTek’s CeraSurf-p is an implant grade alumina matrix composite ceramic material that falls under the ISO 6474-2 Type X (extra high strength) material standard. The proprietary material… […]
  • Life Spine launches sacroiliac screw study
    Life Spine (Huntley, Ill.) said it has begun a study of sacroiliac joint fixation outcomes using its SImpact screw. SImpact is a cannulated and fenestrated screw, intended for sacroiliac joint fusion for conditions including sacroiliac joint disruptions and degenerative sacroiliitis through a lateral approach. It incorporates the proprietary surface technology Osseo-Loc, and is available in… […]
  • Olympus named 2019 Edison Awards finalist
    Olympus recently announced that its EndoEye Flex 3D and its FlexDex Needle Driver have been named a finalist in this year’s Edison Awards. The Edison Awards recognize innovation, creativity and ingenuity in today’s global economy. “Olympus is creating value by offering a cost alternative to robotic surgery through its innovative combination of EndoEye Flex 3D… […]
  • Tegra Medical appoints new general manager
    Tegra Medical has appointed Hal Blenkhorn as its general manager at Tegra’s Franklin, Mass. location. Blenkhorn will report to president and CEO J. Mark King and will be responsible for its local management team and plant operations. He originally joined the company in 2006 as a manufacturing engineer and was later promoted to manufacturing engineering director… […]
  • FDA approves BD’s arteriovenous fistula system
    Becton Dickinson & Co. (NYSE:BDX) said that FDA has cleared its WavelinQ 4 French (4F) endovascular arteriovenous fistula (endoAVF) system for people with end-stage renal disease (ESRD). The 4F endoAVF will allow for the creation of a  fistula in either the ulnar artery and ulnar vein or the radial artery and radial vein, providing a minimally… […]
  • How facial skin wounds could be healed with 3D-bioprinted masks
    Scientists at Wake Forest Institute for Regenerative Medicine (WFIRM) have created a 3D-bioprinted BioMask that could treat facial wounds or burns with tissue regenerated from the mask. The BioMask was developed using a customized, bioengineered skin substitute in combination with a wound dressing layer that can snugly fit onto a facial wound to regenerate skin,… […]

Leave a Reply Cancel reply

You must be logged in to post a comment.

Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by @MassDevice

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing

MASSDEVICE

Subscribe to MassDevice
Advertise with us
About
Contact us
Privacy
Add us on FacebookMassDevice Network
Follow us on Twitter@MassDevice
Connect with us on LinkedInLinkedIn
Follow us on YouTube YouTube

Copyright © 2019 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS